查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018446

藥物輸送裝置市場：依產品類型、治療領域、最終用戶和通路分類－2026-2032年全球市場預測

Drug Delivery Devices Market by Product Type, Therapeutic Area, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物輸送設備市場價值將達到 2,785.5 億美元，到 2026 年將成長至 3,100.7 億美元，到 2032 年將達到 5,993.7 億美元，複合年成長率為 11.56%。

主要市場統計數據
基準年 2025 2785.5億美元
預計年份：2026年 3100.7億美元
預測年份 2032 5993.7億美元
複合年成長率 (%) 11.56%

綜合介紹監管、臨床和技術方面的壓力如何匯聚並重塑藥物輸送設備領域所有相關人員的策略重點。

在製藥技術進步、患者期望和生產流程發展的推動下，藥物傳輸裝置的格局正在迅速且多元化地變化。裝置開發商和醫療機構日益關注兩大挑戰：改善治療效果和降低整體醫療成本。這促使市場對能夠處理複雜生物製藥、延長治療時間並提高用藥依從性的精密輸送系統的需求不斷成長。同時，監管機構發布了更新的指南，強調醫療設備-藥物組合的安全性、人體工學和上市後監測，促使製造商採用更完善的設計和風險管理措施。

生物製藥需求、數位化連接、以病人為中心的設計以及永續製造的融合，如何從整體上改變醫療設備的開發？

在藥物輸送裝置領域，一場變革正在發生，它不再局限於產品的漸進式改進，而是從系統層面改變了治療方法的研發、輸送和監測方式。這場變革的關鍵軸心之一是生物製藥和複合製劑的興起。這些製劑需要精準給藥、特殊材料和整合式輸送機制，這給那些在藥物科學、器械工程和監管策略方面擁有強大跨領域能力的公司帶來了壓力。同時，以患者為中心的設計正從“理想”轉變為“必要”，易用性、便攜性和支持用藥依從性的功能正成為採購和臨床醫生採納的關鍵差異化因素。

本檢驗了近期關稅變化如何促使醫療設備製造商全面重組供應鏈、實現供應商多元化並改變其協作設計流程。

近期關稅政策的累積影響正促使藥物輸送設備產業的整個供應鏈、製造地和籌資策略進行策略性重新評估。從精密玻璃和聚合物原料到電子感測器模組，進口零件關稅帶來的成本壓力正促使醫療設備製造商及其供應商考慮短期採購調整和長期地域多元化。為此，許多機構正在加快加強區域生產能力、選擇替代供應商並擴大庫存緩衝，以期在維持關鍵治療項目生產連續性的同時，降低短期波動風險。

全面的細分分析揭示了設備生產能力、機制、材料選擇和臨床應用如何共同決定其發展和監管路徑。

對細分市場的詳細分析揭示了產品外形規格和使用模式如何影響設計優先順序、監管路徑和商業化策略。在預填充式注射器領域，產品按容量類別區分：具體而言，小於1毫升的小容量注射器用於微生物製藥；1-2.5毫升的標準容量注射器用於一般皮下治療；超過2.5毫升的大容量注射器用於高濃度製劑。同時，藥物類別（例如生物製藥和小分子化合物）的差異決定了材料的相容性和穩定性要求。材料的選擇（從傳統玻璃到先進聚合物）會影響抗破損性、萃取和洗脫測試以及注射器形狀，從而在患者安全性和生產規模化之間做出權衡。

美洲、歐洲、中東和非洲以及亞太市場的區域趨勢需要差異化的監管、製造和商業策略。

區域趨勢在策略規劃中至關重要，因為管理體制、支付方預期和生產生態系統因地區而異。在美洲，成熟的支付方環境和對需要精準給藥方案的先進治療方法的廣泛應用正在推動市場需求。該地區還擁有大量的臨床試驗活動和強勁的創業投資投資，這些因素共同加速了新型給藥平台的商業化。監管機構強調安全性、上市後監測和真實世界數據 (RWE) 的生成，這促使製造商優先考慮可靠的臨床檢驗和可互通的數據收集，以支援報銷談判。

企業級策略洞察凸顯了平台智慧財產權、合作夥伴生態系統以及以服務為導向的差異化在醫療設備競爭格局中日益成長的重要性。

成熟製造商、專業醫療設備開發商和垂直整合型製藥公司之間的競爭凸顯了策略差異化的重要性。主要企業正日益整合其核心優勢——材料科學、精密工程和臨床證據生成——以建構超越單一醫療設備模型的、具有競爭優勢的產品平台。與合約研發生產機構 (CDMO)、數位醫療供應商和學術研究機構夥伴關係已成為常態，這有助於加快迭代周期，並在不增加過高固定成本負擔的情況下獲得專業能力。同時，與藥品和醫療設備整合、感測器演算法和新型運作機制相關的智慧財產權組合正成為影響企業價值、授權機會和合作條款的核心策略資產。

為降低產品專案風險和加快部署速度，提出切實可行的建議，以協調跨職能管治、模組化工程、供應商多元化和數位化。

產業領導企業應採取一系列重點突出、切實可行的措施，在保持競爭力的同時降低執行風險。首先，將研發、法規遵循和供應鏈職能整合到通用的專案管治下，並在設計初期就將採購限制、檢驗計畫和應用需求納入設計決策。這種跨職能協作將減少後期開發階段的意外問題，並加速產品上市速度。其次，優先採用模組化設計，支援材料替換和組件級升級，從而能夠在無需徹底重新設計的情況下，快速應對供應中斷和法規變更。

為了確保實用見解，我們採用了一種透明的混合方法，結合了專家訪談、第二手資料檢驗、細分交叉引用和道德保障措施。

本分析的調查方法結合了第一手和第二手研究方法，並採用嚴謹的方法論以確保其可靠性和有效性。第一手研究主要包括對醫療設備開發商、契約製造、監管專家、臨床醫生和採購經理進行結構化訪談，以獲得關於設計權衡、供應鏈趨勢和市場推廣促進因素的第一手觀點。第二手研究整合了同行評審文獻、監管指導文件、行業協會資料和企業資訊披露，以闡明趨勢並檢驗訪談結果。在整個分析過程中，我們運用了資料檢驗來協調不同的觀點，並找出共識領域和需要積極討論的領域。

總之，策略挑戰的整合強調跨學科能力建構、彈性採購以及在整個醫療設備產品組合中基於證據的商業化。

總之，藥物輸送裝置領域呈現日益複雜和機會加速湧現的特徵。材料、電子和藥物科學領域的技術進步使得更精準、更人性化的給藥方式成為可能，而不斷變化的臨床需求和監管要求也同時提高了實證醫學和品質系統的標準。供應鏈壓力和關稅趨勢凸顯了彈性籌資策略以及設計與採購之間更緊密合作的重要性，而區域差異則要求採用適應性強的商業化模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物輸送裝置市場：依產品類型分類

  • 注射裝置
    • 注射器
      • 傳統注射器
      • 安全注射器
      • 預填充式注射器
    • 筆式注射器
      • 一次性筆式注射器
      • 可重複使用的筆式注射器
    • 自動注射器
      • 一次性自動注射器
      • 可重複使用的自動注射器
    • 無針注射器
  • 點滴裝置
    • 外置輸液泵
      • 胰島素幫浦
      • 攜帶式輸液泵
      • 正排量輸液泵
      • 注射器式輸液泵
    • 植入式輸液泵
  • 吸入裝置
    • 定量吸入器
    • 乾粉吸入器
    • 噴霧器
      • 噴射式霧化器
      • 超音波霧化器
      • 篩孔式噴霧器
  • 經皮給藥裝置
    • 被動式經皮貼片
    • 活性經皮吸收系統
      • 微針貼片
      • 離子泳動裝置
  • 嵌入式裝置
    • 可生物分解植入
    • 不可生物分解的植入

第9章：藥物輸送裝置市場：依治療領域分類

  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 腫瘤學
    • 固態腫瘤
    • 骨髓惡性腫瘤
  • 心血管疾病
    • 高血壓
    • 心臟衰竭
  • 呼吸系統疾病
    • 氣喘
    • 慢性阻塞性肺病
    • 囊腫纖維化
  • 自體免疫/發炎性疾病
    • 類風濕性關節炎
    • 多發性硬化症
    • 發炎性腸道疾病
  • 感染疾病
    • 病毒感染疾病
    • 細菌感染疾病
  • 神經系統疾病
    • 癲癇
    • 帕金森氏症
    • 阿茲海默症
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
  • 荷爾蒙失調
    • 生長激素缺乏症
    • 生殖荷爾蒙失調

第10章 藥物輸送設備市場：依最終用戶分類

  • 醫院
    • 三級醫療醫院
    • 二級醫療醫院
  • 診所
    • 專科診所
    • 初級保健診所
  • 門診手術中心
  • 居家照護環境
    • 自我管理
    • 由上門護理師進行管理
  • 診斷中心
  • 長期照護機構
    • 護理機構
    • 復健中心

第11章 藥物傳輸設備市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房
  • 網路藥房

第12章 藥物輸送設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 藥物傳輸裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 藥物輸送設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：藥物傳輸設備市場

第16章 中國：藥物輸送裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • AptarGroup, Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Bespak Europe Ltd.
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Haselmeier GmbH
  • Insulet Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co., Inc.
  • Nemera France SAS
  • Novartis AG
  • Owen Mumford Ltd.
  • Pfizer Inc.
  • Portal Instruments, Inc.
  • Roche Diabetes Care, Inc.
  • Sanofi SA
  • SHL Medical AG
  • Tandem Diabetes Care, Inc.
  • West Pharmaceutical Services, Inc.
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-B812DD5799B4

The Drug Delivery Devices Market was valued at USD 278.55 billion in 2025 and is projected to grow to USD 310.07 billion in 2026, with a CAGR of 11.56%, reaching USD 599.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 278.55 billion
Estimated Year [2026] USD 310.07 billion
Forecast Year [2032] USD 599.37 billion
CAGR (%) 11.56%

An integrated introduction framing how converging regulatory, clinical, and technology pressures are reshaping strategic priorities across drug delivery device stakeholders

The drug delivery device landscape is evolving at a rapid and multidimensional pace, driven by advances in pharmaceuticals, patient expectations, and manufacturing technologies. Device developers and healthcare organizations are increasingly aligning around the twin imperatives of improving therapeutic outcomes and reducing total cost of care, which has heightened demand for precision delivery systems that can support complex biologics, extend therapeutic windows, and improve adherence. In parallel, regulators have responded with updated guidance that emphasizes device-drug combination safety, human factors engineering, and post-market surveillance, prompting manufacturers to adopt more robust design control and risk management practices.

Consequently, stakeholders across the value chain are recalibrating priorities: design teams are integrating connectivity and usability testing earlier in development, procurement groups are pursuing more resilient supply relationships, and clinical teams are seeking devices that simplify administration without compromising safety. These shifts are underpinned by technology trends such as polymer innovation, microfluidics, and low-power electronics, which enable smaller footprints and enhanced dosing accuracy. Together, these forces are reshaping competitive dynamics, opening new routes for differentiation while also raising the bar for regulatory documentation and quality systems.

This introduction frames the subsequent analysis, which explores structural shifts, tariff-related impacts, segmentation-specific dynamics, regional patterns, and tactical recommendations for organizations seeking to navigate the near-term horizon with confidence and strategic clarity.

How convergence of biologics demand, digital connectivity, patient-centric design, and sustainable manufacturing is driving systemic transformation across device development

The landscape for drug delivery devices is experiencing transformative shifts that extend beyond incremental product improvements and into systemic changes in how therapies are developed, delivered, and monitored. A primary axis of change is the rise of biologic therapies and combination products that demand precision dosing, specialized materials, and integrated delivery mechanisms-pressures that favor companies with strong cross-functional capabilities in formulation science, device engineering, and regulatory strategy. At the same time, patient-centric design has moved from a nice-to-have to a core requirement, with usability, portability, and adherence-supporting features becoming decisive differentiators in procurement and clinician adoption.

Digitization and connectivity represent another inflection point. Embedded sensors, Bluetooth-enabled data capture, and cloud analytics are enabling closed-loop therapies, remote monitoring, and real-world evidence generation, thereby creating new value propositions for payers and providers. Sustainability considerations are also shaping R&D and procurement choices, with materials selection and end-of-life strategies increasingly influencing product roadmaps. Meanwhile, manufacturing innovations such as advanced polymer processing, automation, and modular cleanroom systems are lowering barriers to flexible scale-up and near-shoring efforts.

Collectively, these shifts demand more integrated cross-disciplinary capabilities across companies and their partners. Organizations that align product innovation with regulatory foresight, supply chain resilience, and digital ecosystems will be best positioned to capture clinical and commercial value in this new era.

Examining how recent tariff shifts have catalyzed supply chain restructuring, supplier diversification, and collaborative design changes across device manufacturers

The cumulative impact of recent tariff policies has prompted a strategic reassessment across drug delivery device supply chains, manufacturing footprints, and sourcing strategies. Tariff-driven cost pressures on imported components-ranging from precision glass and polymeric raw materials to electronic sensor modules-have incentivized device makers and their suppliers to evaluate near-term procurement adjustments and longer-term geographic diversification. In response, many organizations are accelerating regional manufacturing capabilities, qualifying alternate suppliers, and increasing inventory buffers to mitigate short-term volatility while preserving production continuity for critical therapeutic programs.

Beyond immediate cost implications, tariffs have also influenced product design choices. Engineers and sourcing teams are collaborating more closely to identify material substitutions and design optimizations that reduce dependence on tariff-exposed inputs while maintaining regulatory compliance and clinical performance. This collaborative approach extends to contract manufacturers and suppliers, where tighter supplier agreements, shared investment in tooling, and joint risk assessments have become common tactics for preserving program timelines and controlling total landed costs.

Regulatory considerations remain central in this environment: any material or supplier change carries implications for device validation, stability testing, and submission content. Therefore, organizations are building stronger cross-functional governance between regulatory, quality, and supply chain to accelerate change control while managing compliance risk. Overall, the tariff landscape is catalyzing a shift toward greater supply chain agility and closer integration between design and procurement functions.

Comprehensive segmentation analysis revealing how device capacity, mechanism, material selection, and clinical application jointly dictate development and regulatory pathways

A nuanced look at segmentation reveals how product form factors and usage paradigms are shaping design priorities, regulatory pathways, and commercialization strategies. In the pre-filled syringe domain, devices are differentiated by capacity categories-smaller volumes under one milliliter for precise biologic microdosing, standard 1-2.5 milliliter formats for common subcutaneous therapies, and larger >2.5 milliliter formats for concentrated formulations-while drug class distinctions between biologics and small molecules determine material compatibility and stability requirements. Material selection between traditional glass and advanced polymers carries implications for breakage resistance, extractables and leachables testing, and syringe geometry, driving trade-offs between patient safety and manufacturing scalability.

Auto-injector segmentation centers on drug type and actuation mechanisms: products supporting epinephrine require rapid, single-use deployment characteristics and robust force profiles, whereas insulin auto-injectors emphasize dose titration and ease of repeated use. Mechanism choices between gas-powered and spring-driven systems influence device complexity, manufacturing costs, and maintenance considerations, and therefore shape both clinical training needs and lifecycle support models. For inhalers, clinical application across allergic rhinitis, asthma, and COPD dictates dose frequency, aerosol performance, and patient interface ergonomics, while device types such as dry powder inhalers, pressurized metered dose inhalers, and soft mist inhalers present divergent engineering, propellant, and formulation constraints.

Pen injectors are segmented by application and usability paradigms: diabetes-focused devices prioritize dose accuracy, ergonomic designs, and compatibility with insulin formulations, while growth hormone pens emphasize multi-dose stability and pediatric-friendly interfaces; disposable and reusable types entail different service and sterilization strategies. Insulin pumps are classified by form factor and integration level-implantable, patch, and tethered models-each with distinct power, battery life, and closed-loop control challenges. Nebulizers vary across jet, mesh, and ultrasonic technologies, with trade-offs in aerosol particle size distribution, portability, and maintenance. Transdermal systems span matrix, microneedle, and reservoir architectures, presenting distinct pharmacokinetic control and regulatory evidence needs. Finally, jet injectors differentiate based on mechanism choices between gas-powered and spring-loaded systems, which influence dosing profiles, user training, and device lifecycle considerations. Understanding these layered segmentation nuances is essential for aligning product development, regulatory strategy, and market entry sequencing.

Regional dynamics that require differentiated regulatory, manufacturing, and commercial strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic dynamics are critical for strategic planning because regulatory regimes, payer expectations, and manufacturing ecosystems vary meaningfully across regions. In the Americas, demand is shaped by a mature payer environment and significant adoption of advanced therapies that require precise delivery solutions; this region also houses major clinical trial activity and strong venture capital flows, which together accelerate commercialization timelines for novel delivery platforms. Regulatory authorities emphasize safety, post-market surveillance, and real-world evidence generation, prompting manufacturers to prioritize robust clinical validation and interoperable data capture to support reimbursement discussions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization within some markets contrasts with divergent requirements elsewhere. European markets often lead on sustainability initiatives and human factors expectations, raising the bar for device lifecycle management and materials stewardship. The Middle East and Africa display uneven infrastructure and market access dynamics, which require tailored distribution strategies, local partnership models, and adaptive pricing approaches. Across this broader region, multilingual labeling, diverse clinical practice patterns, and variable procurement frameworks necessitate flexible commercial models and strong local regulatory expertise.

Asia-Pacific represents a mix of advanced manufacturing capacity, rapid adoption of mobile health technologies, and expanding domestic demand for chronic disease management tools. Several countries in this region are investing in domestic production and regulatory modernization, which can speed product approvals but also raise competitive pressures from local manufacturers. In aggregate, regional strategies must balance centralized R&D and quality control with decentralized commercialization tactics to meet divergent regulatory timelines and clinical preferences.

Strategic company-level insights highlighting the growing importance of platform IP, partner ecosystems, and service-oriented differentiation in device competition

Competitive dynamics among established manufacturers, specialty device developers, and vertically integrated pharmaceutical firms underscore the importance of strategic differentiation. Leading companies are increasingly combining core competencies-such as materials science, precision engineering, and clinical evidence generation-to create defensible product platforms that extend beyond single-device models. Partnerships and alliances with contract development and manufacturing organizations, digital health vendors, and academic research institutions are common, enabling faster iteration cycles and access to specialized capabilities without carrying excessive fixed-cost burdens. At the same time, intellectual property portfolios around drug-device integration, sensor algorithms, and novel actuation mechanisms are becoming central strategic assets that influence valuation, licensing opportunities, and collaboration terms.

Mergers and acquisitions continue to be an important route for capability acquisition, but owners now weigh integration complexity, cultural fit, and regulatory obligations more heavily than in prior cycles. Service-oriented offerings, including training, remote monitoring, and post-market analytics, are evolving into differentiators that tie customers to vendor platforms and create recurring revenue streams. Companies that demonstrate operational excellence in quality systems, complaint handling, and regulatory submissions tend to gain trust with large pharmaceutical partners seeking device co-development. Finally, nimble mid-sized firms that can rapidly prototype and conduct iterative user testing are attractive partners for larger organizations seeking to accelerate time-to-proof-of-concept and reduce internal development risk.

Actionable recommendations that align cross-functional governance, modular engineering, supplier diversification, and digital enablement to de-risk product programs and accelerate adoption

Industry leaders should adopt a set of focused, executable actions to maintain competitiveness while reducing execution risk. First, align R&D, regulatory, and supply chain functions under shared program governance so that design choices account for sourcing constraints, validation timelines, and submission requirements from day one. This cross-functional alignment reduces late-stage surprises and accelerates product readiness. Second, prioritize modular design that supports both material substitution and component-level upgrades, enabling rapid response to supply disruptions and regulatory changes without full redesign.

Third, invest selectively in digital enablement that provides tangible clinical or operational benefits-such as adherence monitoring, remote dose adjustment, or predictive maintenance-while ensuring data interoperability and clear evidence generation plans to support reimbursement discussions. Fourth, broaden supplier qualification efforts geographically and contractually, incorporating dual-sourcing where feasible and engaging in risk-sharing arrangements to protect critical programs. Fifth, build clear sustainability roadmaps that target high-impact materials and end-of-life strategies, linking these efforts to procurement requirements and product labeling to meet increasing stakeholder scrutiny.

Finally, adopt an evidence-driven commercialization approach: prioritize early human factors testing, gather real-world performance metrics, and develop value narratives tailored to clinicians, payers, and patients. By implementing these recommendations, leaders can reduce technical and commercial risk, improve responsiveness to regulatory shifts, and create differentiated value propositions that resonate across stakeholders.

A transparent mixed-methods approach combining expert interviews, secondary validation, segmentation cross-referencing, and ethical safeguards to ensure actionable insights

The research methodology underpinning this analysis combined primary and secondary approaches with methodological rigor to ensure reliability and relevance. Primary inputs included structured interviews with device developers, contract manufacturers, regulatory professionals, clinicians, and procurement leaders, providing firsthand perspectives on design trade-offs, supply chain dynamics, and adoption drivers. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, trade association materials, and company disclosures to contextualize trends and validate interview findings. Data triangulation was applied throughout to reconcile differing viewpoints and to highlight consensus versus areas of active debate.

Segment mapping was carried out by cross-referencing product form factors, clinical applications, and mechanism typologies to ensure that each segment reflected practical engineering and usage distinctions. Quality assurance steps included independent expert reviews of the segmentation framework and spot checks against recent product approvals and technical white papers. Limitations of the approach are acknowledged: insights are informed by available expert perspectives and public documentation, and rapidly evolving regulatory or geopolitical events can alter assumptions between research completion and report access. To mitigate this, the methodology emphasizes transparent sourcing, date-stamping of key inputs, and a focus on durable structural trends rather than transient market fluctuations.

Ethical considerations were observed throughout, with interview participants engaged under agreed confidentiality terms and proprietary information treated according to nondisclosure protocols. The result is an evidence-informed analysis designed to support strategic decision making while recognizing inherent uncertainties in technology and policy evolution.

Concluding synthesis of strategic imperatives emphasizing multidisciplinary capability building, resilient sourcing, and evidence-driven commercialization across device portfolios

In conclusion, the drug delivery device environment is characterized by accelerating complexity and opportunity. Technological advances in materials, electronics, and formulation science are enabling more precise and patient-friendly delivery approaches, while evolving clinical needs and regulatory expectations are simultaneously raising the threshold for evidence and quality systems. Supply chain pressures and tariff dynamics underscore the importance of resilient sourcing strategies and tighter integration between design and procurement, and regional heterogeneity necessitates adaptable commercialization models.

Organizations that succeed will be those that build multidisciplinary capabilities, prioritize modular and adaptable design architectures, and pursue partnerships that extend technical and regulatory reach. Investments in data-enabled services and sustainability will increasingly differentiate providers, and a disciplined approach to supplier diversification will reduce exposure to external shocks. Ultimately, the path to durable competitive advantage lies in aligning clinical value, regulatory readiness, manufacturing resilience, and commercial clarity, enabling device developers to deliver safer, more effective, and more accessible therapies to patients.

This conclusion synthesizes the strategic implications presented earlier and underscores the importance of proactive, evidence-based planning as the industry navigates the near-term horizon.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Delivery Devices Market, by Product Type

  • 8.1. Injection Devices
    • 8.1.1. Syringes
      • 8.1.1.1. Conventional Syringes
      • 8.1.1.2. Safety Syringes
      • 8.1.1.3. Prefilled Syringes
    • 8.1.2. Pen Injectors
      • 8.1.2.1. Disposable Pen Injectors
      • 8.1.2.2. Reusable Pen Injectors
    • 8.1.3. Autoinjectors
      • 8.1.3.1. Disposable Autoinjectors
      • 8.1.3.2. Reusable Autoinjectors
    • 8.1.4. Needle-Free Injectors
  • 8.2. Infusion Devices
    • 8.2.1. External Infusion Pumps
      • 8.2.1.1. Insulin Pumps
      • 8.2.1.2. Ambulatory Infusion Pumps
      • 8.2.1.3. Volumetric Infusion Pumps
      • 8.2.1.4. Syringe Infusion Pumps
    • 8.2.2. Implantable Infusion Pumps
  • 8.3. Inhalation Devices
    • 8.3.1. Metered Dose Inhalers
    • 8.3.2. Dry Powder Inhalers
    • 8.3.3. Nebulizers
      • 8.3.3.1. Jet Nebulizers
      • 8.3.3.2. Ultrasonic Nebulizers
      • 8.3.3.3. Mesh Nebulizers
  • 8.4. Transdermal Delivery Devices
    • 8.4.1. Passive Transdermal Patches
    • 8.4.2. Active Transdermal Systems
      • 8.4.2.1. Microneedle Patches
      • 8.4.2.2. Iontophoresis Devices
  • 8.5. Implantable Devices
    • 8.5.1. Biodegradable Implants
    • 8.5.2. Nonbiodegradable Implants

9. Drug Delivery Devices Market, by Therapeutic Area

  • 9.1. Metabolic Disorders
    • 9.1.1. Diabetes
    • 9.1.2. Obesity
  • 9.2. Oncology
    • 9.2.1. Solid Tumors
    • 9.2.2. Hematologic Malignancies
  • 9.3. Cardiovascular Diseases
    • 9.3.1. Hypertension
    • 9.3.2. Heart Failure
  • 9.4. Respiratory Diseases
    • 9.4.1. Asthma
    • 9.4.2. Chronic Obstructive Pulmonary Disease
    • 9.4.3. Cystic Fibrosis
  • 9.5. Autoimmune And Inflammatory Diseases
    • 9.5.1. Rheumatoid Arthritis
    • 9.5.2. Multiple Sclerosis
    • 9.5.3. Inflammatory Bowel Disease
  • 9.6. Infectious Diseases
    • 9.6.1. Viral Infections
    • 9.6.2. Bacterial Infections
  • 9.7. Neurological Disorders
    • 9.7.1. Epilepsy
    • 9.7.2. Parkinson Disease
    • 9.7.3. Alzheimer Disease
  • 9.8. Pain Management
    • 9.8.1. Acute Pain
    • 9.8.2. Chronic Pain
  • 9.9. Hormonal Disorders
    • 9.9.1. Growth Hormone Deficiency
    • 9.9.2. Reproductive Hormone Disorders

10. Drug Delivery Devices Market, by End User

  • 10.1. Hospitals
    • 10.1.1. Tertiary Care Hospitals
    • 10.1.2. Secondary Care Hospitals
  • 10.2. Clinics
    • 10.2.1. Specialty Clinics
    • 10.2.2. Primary Care Clinics
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Home Care Settings
    • 10.4.1. Self Administration
    • 10.4.2. Home Health Nurse Administration
  • 10.5. Diagnostic Centers
  • 10.6. Long Term Care Facilities
    • 10.6.1. Nursing Homes
    • 10.6.2. Rehabilitation Centers

11. Drug Delivery Devices Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
    • 11.2.1. Chain Pharmacies
    • 11.2.2. Independent Pharmacies
  • 11.3. Online Pharmacies

12. Drug Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drug Delivery Devices Market

16. China Drug Delivery Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. AptarGroup, Inc.
  • 17.7. Baxter International Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Bespak Europe Ltd.
  • 17.10. Gerresheimer AG
  • 17.11. GlaxoSmithKline plc
  • 17.12. Haselmeier GmbH
  • 17.13. Insulet Corporation
  • 17.14. Johnson & Johnson
  • 17.15. Medtronic plc
  • 17.16. Merck & Co., Inc.
  • 17.17. Nemera France S.A.S.
  • 17.18. Novartis AG
  • 17.19. Owen Mumford Ltd.
  • 17.20. Pfizer Inc.
  • 17.21. Portal Instruments, Inc.
  • 17.22. Roche Diabetes Care, Inc.
  • 17.23. Sanofi S.A.
  • 17.24. SHL Medical AG
  • 17.25. Tandem Diabetes Care, Inc.
  • 17.26. West Pharmaceutical Services, Inc.
  • 17.27. West Pharmaceutical Services, Inc.
  • 17.28. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CONVENTIONAL SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CONVENTIONAL SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CONVENTIONAL SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTOINJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTOINJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTOINJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE AUTOINJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE AUTOINJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE AUTOINJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EXTERNAL INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EXTERNAL INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EXTERNAL INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EXTERNAL INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INHALATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INHALATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INHALATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INHALATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL DELIVERY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL DELIVERY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL DELIVERY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PASSIVE TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PASSIVE TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PASSIVE TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACTIVE TRANSDERMAL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACTIVE TRANSDERMAL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACTIVE TRANSDERMAL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACTIVE TRANSDERMAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MICRONEEDLE PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MICRONEEDLE PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IONTOPHORESIS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IONTOPHORESIS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IONTOPHORESIS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BIODEGRADABLE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BIODEGRADABLE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BIODEGRADABLE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NONBIODEGRADABLE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NONBIODEGRADABLE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NONBIODEGRADABLE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HORMONAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REPRODUCTIVE HORMONE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REPRODUCTIVE HORMONE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REPRODUCTIVE HORMONE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME HEALTH NURSE ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME HEALTH NURSE ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOME HEALTH NURSE ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY LONG TERM CARE FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NURSING HOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NURSING HOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY NURSING HOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 281. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 282. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 284. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGES, 2018-2032 (USD MILLION)
  • TABLE 285. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 286. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, 2018-2032 (USD MILLION)
  • TABLE 287. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 288. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY EXTERNAL INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 289. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY INHALATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 290. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 291. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL DELIVERY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 292. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY ACTIVE TRANSDERMAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 295. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. AMERICAS DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. AMERICAS DRUG DE